TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsGlobeNewsWire • Monday
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerGlobeNewsWire • 03/28/24
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentGlobeNewsWire • 03/11/24
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist ImmunotherapeuticGlobeNewsWire • 02/20/24
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock MarketGlobeNewsWire • 01/31/24
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerGlobeNewsWire • 01/29/24
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEOGlobeNewsWire • 01/12/24
TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and ObjectivesGlobeNewsWire • 01/04/24
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138GlobeNewsWire • 12/12/23
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/05/23
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 12/04/23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 11/30/23
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business UpdateGlobeNewsWire • 11/14/23
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to ConditionsGlobeNewsWire • 10/27/23
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138GlobeNewsWire • 10/26/23
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138GlobeNewsWire • 10/24/23